ES2426008T5 - Tratamiento de síntomas de la enfermedad de Parkinson con ligandos del receptor de histamina H3 de alquilaminas no imidazólicas - Google Patents

Tratamiento de síntomas de la enfermedad de Parkinson con ligandos del receptor de histamina H3 de alquilaminas no imidazólicas Download PDF

Info

Publication number
ES2426008T5
ES2426008T5 ES06744466T ES06744466T ES2426008T5 ES 2426008 T5 ES2426008 T5 ES 2426008T5 ES 06744466 T ES06744466 T ES 06744466T ES 06744466 T ES06744466 T ES 06744466T ES 2426008 T5 ES2426008 T5 ES 2426008T5
Authority
ES
Spain
Prior art keywords
compound
treatment
parkinson
disease
sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06744466T
Other languages
English (en)
Spanish (es)
Other versions
ES2426008T3 (es
Inventor
Jean-Charles Schwartz
Jeanne-Marie Lecomte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioprojet SC
Original Assignee
Bioprojet SC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35169680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2426008(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioprojet SC filed Critical Bioprojet SC
Publication of ES2426008T3 publication Critical patent/ES2426008T3/es
Application granted granted Critical
Publication of ES2426008T5 publication Critical patent/ES2426008T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES06744466T 2005-04-01 2006-03-30 Tratamiento de síntomas de la enfermedad de Parkinson con ligandos del receptor de histamina H3 de alquilaminas no imidazólicas Expired - Lifetime ES2426008T5 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05290727A EP1707203A1 (en) 2005-04-01 2005-04-01 Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
EP05290727 2005-04-01
US66861805P 2005-04-06 2005-04-06
US668618P 2005-04-06
PCT/IB2006/000739 WO2006103546A2 (en) 2005-04-01 2006-03-30 Treatment of parkinson's disease, obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine h3-receptor ligands

Publications (2)

Publication Number Publication Date
ES2426008T3 ES2426008T3 (es) 2013-10-18
ES2426008T5 true ES2426008T5 (es) 2020-03-20

Family

ID=35169680

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06744466T Expired - Lifetime ES2426008T5 (es) 2005-04-01 2006-03-30 Tratamiento de síntomas de la enfermedad de Parkinson con ligandos del receptor de histamina H3 de alquilaminas no imidazólicas

Country Status (27)

Country Link
US (1) US8486947B2 (enExample)
EP (2) EP1707203A1 (enExample)
JP (3) JP5546761B2 (enExample)
KR (1) KR101308527B1 (enExample)
CN (1) CN101171009B (enExample)
AU (1) AU2006228413C1 (enExample)
BR (1) BRPI0612216B1 (enExample)
CA (1) CA2603656C (enExample)
CY (1) CY1114636T1 (enExample)
DK (1) DK1863487T4 (enExample)
EA (1) EA016007B1 (enExample)
ES (1) ES2426008T5 (enExample)
HR (1) HRP20130748T4 (enExample)
MA (1) MA29353B1 (enExample)
ME (1) ME01713B (enExample)
MX (1) MX2007012162A (enExample)
NO (1) NO343603B1 (enExample)
NZ (1) NZ561940A (enExample)
PL (1) PL1863487T5 (enExample)
PT (1) PT1863487E (enExample)
RS (1) RS52911B2 (enExample)
SG (1) SG147415A1 (enExample)
SI (1) SI1863487T2 (enExample)
TN (1) TNSN07365A1 (enExample)
UA (1) UA94902C2 (enExample)
WO (1) WO2006103546A2 (enExample)
ZA (1) ZA200708086B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
CA2655604C (en) 2006-06-23 2016-08-09 Abbott Laboratories Cyclopropyl amine derivatives
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
MX2009000884A (es) 2006-07-25 2009-06-05 Cephalon Inc Derivados de piridizinona.
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
EP2250176B1 (en) 2008-01-30 2012-08-01 Cephalon, Inc. Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
FR2932479A1 (fr) * 2008-06-13 2009-12-18 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2012037258A1 (en) 2010-09-16 2012-03-22 Abbott Laboratories Processes for preparing 1,2-substituted cyclopropyl derivatives
US9181275B2 (en) 2011-08-11 2015-11-10 Abbvie Inc. Mercaptoamidine derivatives and methods of use
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
AU2013327450B2 (en) * 2012-10-05 2018-07-12 Vtv Therapeutics Llc Treatment of mild and moderate Alzheimer's disease
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder
US11266837B2 (en) 2019-03-06 2022-03-08 Medtronic Xomed, Inc. Position sensitive lingual muscle simulation system for obstructive sleep apnea
EP4248969A1 (en) 2022-03-23 2023-09-27 Bioprojet Use of pitolisant for treating severe fatigue
CN121175294A (zh) 2023-03-31 2025-12-19 生物计划制药公司 盐酸替洛利生的多晶型形式
TW202535386A (zh) 2023-10-16 2025-09-16 法商拜爾普羅傑特醫藥有限公司 腸溶包衣必托里賽（ｐｉｔｏｌｉｓａｎｔ）調配物及使用方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815945A (ja) * 1981-07-21 1983-01-29 Teikoku Hormone Mfg Co Ltd 新規なフエノキシアルキルアミン誘導体
FR2579596B1 (fr) 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2671083B1 (fr) 1990-12-31 1994-12-23 Inst Nat Sante Rech Med Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
EP0573542B1 (en) 1991-02-27 1997-10-15 Seed Capital Investments( Sci) B.V. Imidazole-derivatives having antagonistic activity on the histamine h3-receptor
KR0142801B1 (en) 1991-12-18 1998-07-15 Schering Corp Imidazoylalkyl substituted with a six membered nitrogen containing heterocyclic ring t
NZ246441A (en) 1991-12-18 1996-02-27 Schering Corp Imidazol or imidazolalkyl substituted with a 4 or 5 membered nitrogen containing heterocycle, preparation and pharmaceutical compositions thereof
FR2686084B1 (fr) 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5486526A (en) * 1992-04-01 1996-01-23 The University Of Toledo Histamine H3 -receptor antagonists and therapeutic uses thereof
US5380858A (en) 1992-04-01 1995-01-10 The University Of Toledo Process for the preparation of intermediates useful for the synthesis of histamine receptor antagonists
US5639775A (en) 1992-04-01 1997-06-17 The University Of Toledo 4-[4'-piperodinyl or 3'-pirrolidinyl] substituted imidazoles as H3 -receptor antagonists and therapeutic uses thereof
EP0680960A4 (en) 1993-01-25 1997-05-14 Green Cross Corp IMIDAZOLE CONNECTION.
JP3522790B2 (ja) 1993-06-08 2004-04-26 花王株式会社 Ｈ３−レセプター刺激薬
AU7823894A (en) 1993-08-27 1995-03-21 Vrije Universiteit New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor
GB9319534D0 (en) * 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
NZ276883A (en) 1993-11-15 1998-08-26 Schering Corp 1h-imidazol-4-yl)alkyl]benzene derivatives
GB9411045D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
PT841922E (pt) 1995-05-30 2002-07-31 Gliatech Inc Derivados de ih-imidazole 4(5)-substituidos
US5652258A (en) 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
ES2184876T3 (es) 1995-06-07 2003-04-16 Gliatech Inc Derivados de imidazol sustituidos en 1h-4(5).
AU709611B2 (en) 1996-02-09 1999-09-02 James Black Foundation Limited Histamine h3 receptor ligands
JP3925579B2 (ja) * 1998-02-03 2007-06-06 日本精工株式会社 潤滑剤供給体、並びに前記潤滑剤供給体を備える転がり軸受、リニアガイド装置及びボールねじ装置
EP0982300A3 (en) * 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
US6136559A (en) * 1998-10-07 2000-10-24 Ortho Pharmaceutical Corporation DNA encoding as human histamine receptor of the H3 subtype
AU770234B2 (en) * 1999-06-11 2004-02-19 Toyama Chemical Co. Ltd. N-alkoxyalkyl-N, N-dialkylamine derivatives or salts thereof and agents for treating neurodegenerative diseases comprising the same
GB9924941D0 (en) * 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
US6620839B2 (en) * 2000-07-13 2003-09-16 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
ATE319696T1 (de) * 2000-08-08 2006-03-15 Ortho Mcneil Pharm Inc Nicht-imidazol aryloxyalkylamine als h3 rezeptor liganden
CA2419073A1 (en) * 2000-08-17 2002-02-21 Gliatech, Inc. Novel alicyclic imidazoles as h3 agents
AU2001283573A1 (en) * 2000-08-21 2002-03-04 Gliatech, Inc. The use of histamine H3 receptor inverse agonists for the control of appetite and treatment of obesity
CA2442326C (en) * 2001-03-29 2012-05-22 Ortho-Mcneil Pharmaceutical, Inc. Imidazolyl derivatives useful as histamine h3 receptor ligands
AU2002228698A1 (en) * 2001-11-15 2003-06-10 Ortho-Mcneil Pharmaceutical, Inc. Agonists of recombinant human histamine h3 receptor
CA2469893A1 (en) * 2001-12-10 2003-06-19 Ortho-Mcneil Pharmaceutical, Inc. Phenylalkynes
EP1556046A1 (en) * 2002-10-23 2005-07-27 Janssen Pharmaceutica N.V. Phenylpiperidines and phenylpyrrolidines as histamine h3 receptor modulators
FR2856596B1 (fr) * 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
CA2529790A1 (en) * 2003-06-27 2005-01-27 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy nitrogenous saturated heterocyclic derivative
SE0302116D0 (sv) * 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
JP4765627B2 (ja) * 2003-09-22 2011-09-07 Ｍｓｄ株式会社 新規ピペリジン誘導体

Also Published As

Publication number Publication date
SG147415A1 (en) 2008-11-28
WO2006103546A3 (en) 2007-03-01
JP5546761B2 (ja) 2014-07-09
CY1114636T1 (el) 2016-10-05
JP2014062126A (ja) 2014-04-10
SI1863487T2 (sl) 2019-11-29
DK1863487T4 (da) 2019-10-14
KR101308527B1 (ko) 2013-09-17
TNSN07365A1 (fr) 2008-12-31
CA2603656A1 (en) 2006-10-05
CN101171009B (zh) 2012-11-07
NO20075086L (no) 2007-12-27
AU2006228413B2 (en) 2011-09-15
RS52911B (sr) 2014-02-28
RS52911B2 (sr) 2019-11-29
EP1863487A2 (en) 2007-12-12
HRP20130748T1 (en) 2013-10-11
UA94902C2 (ru) 2011-06-25
PL1863487T3 (pl) 2014-10-31
KR20080002904A (ko) 2008-01-04
EA016007B1 (ru) 2012-01-30
NO343603B1 (no) 2019-04-08
US8486947B2 (en) 2013-07-16
ME01713B (me) 2014-09-20
AU2006228413A1 (en) 2006-10-05
BRPI0612216A2 (pt) 2010-10-26
HRP20130748T4 (hr) 2019-11-15
EP1863487B2 (en) 2019-07-17
JP5955872B2 (ja) 2016-07-20
ES2426008T3 (es) 2013-10-18
AU2006228413C1 (en) 2012-02-02
JP2016106142A (ja) 2016-06-16
DK1863487T3 (da) 2013-08-12
EP1707203A1 (en) 2006-10-04
ZA200708086B (en) 2008-10-29
WO2006103546A2 (en) 2006-10-05
CN101171009A (zh) 2008-04-30
EA200702135A1 (ru) 2008-04-28
JP2008534572A (ja) 2008-08-28
MX2007012162A (es) 2007-11-22
PT1863487E (pt) 2013-08-29
BRPI0612216B1 (pt) 2022-04-19
MA29353B1 (fr) 2008-03-03
EP1863487B1 (en) 2013-05-29
SI1863487T1 (sl) 2013-09-30
US20090318433A1 (en) 2009-12-24
NZ561940A (en) 2010-06-25
CA2603656C (en) 2015-06-16
PL1863487T5 (pl) 2021-08-09

Similar Documents

Publication Publication Date Title
ES2426008T3 (es) Tratamiento de síntomas de la enfermedad de Parkinson con ligandos del receptor de histamina H3 de alquilaminas no imidazólicas
ES2591110T3 (es) Usos terapéuticos de compuestos que tienen actividad SERT, 5-HT3 y 5-HT1A combinada
ES2208870T3 (es) Uso de antagonistas del receptor 5ht4 para resolver los efectos gastrointestinales de los inhibidores de la reabsorcion de serotonina.
JP2010168404A (ja) 睡眠時無呼吸の薬理学的処置
EP0923370A2 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
JP4896334B2 (ja) 睡眠時呼吸障害を治療及び診断する方法並びにその方法を実施する手段
CN1154485C (zh) 一种特异性的5ht2受体拮抗物在制备治疗睡眠窒息症的药物中的应用
US20020183306A1 (en) Combination treatment for sleep disorders including sleep apnea
CN112930179A (zh) 治疗睡眠呼吸暂停的方法和组合物
WO2016061554A1 (en) Synergistic composition of known, safe pharmaceuticals for use in insomnia and a method of treatment thereof
RU2751504C2 (ru) Применение карбамата для предупреждения или лечения невралгии тройничного нерва
JP2010505844A (ja) Ｓ−ニトロソチオール化合物および関連誘導体
CN110290788A (zh) 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途
CN110267657B (zh) 氨基甲酸酯化合物用于预防、缓解或治疗震颤或震颤综合征的用途
JP5197361B2 (ja) 睡眠障害を処置するための組成物および方法
BR112013000164B1 (pt) Agente terapêutico ou agente profilático
WO2006009093A1 (ja) 睡眠障害の予防および／または治療剤
KR20250057804A (ko) 수면 무호흡증을 치료하기 위한 방법 및 조성물
JP5142991B2 (ja) １−（３−クロロフェニル）−３−アルキルピペラジンを含む食欲障害治療用医薬組成物
WO2024220343A1 (en) Combination of a norepinephrine reuptake inhibitor and a melatonin receptor agonist for use in treating sleep apnea
JP2009501205A (ja) 精神病治療用組成物
HK40015061A (en) Use of carbamate compounds for preventing, alleviating, or treating tremors or tremor syndrome
HK40015061B (en) Use of carbamate compounds for preventing, alleviating, or treating tremors or tremor syndrome
TW200906406A (en) Use of a compound that is a neurokinin A NK2 receptor antagonist for the preparation of medicaments for use in the prevention and treatment of sexual dysfunctions
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder